Looking Ahead: ASCO 2024 Updates and Future Perspectives

Opinion
Video

Experts on multiple myeloma look to the future treatment landscape and discuss exciting updates presented at the 2024 ASCO Annual Meeting, highlighting belantamab mafodotin and combination therapies.

Video content above is prompted by the following question:

  • What are some data updates at ASCO 2024 that you are excited about?
Recent Videos
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Related Content
Daratumumab Plus KRd May Be a New SOC Option in NDMM

Daratumumab Plus KRd May Be a New SOC Option in NDMM

Tim Cortese
June 3rd 2025
Article

Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.

Daratumumab Combo Improves Outcomes in Transplant-Ineligible NDMM Subgroups

Russ Conroy
June 2nd 2025
Article

Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma

Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma

Gina Mauro
June 2nd 2025
Article

PFS was improved with belantamab mafodotin triplet for patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.

The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.

Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma

Roman Fabbricatore
June 1st 2025
Article

The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.